RxDoctor Payments Data

Erica Lapinsky, APRN

Family · Deland, FLNPI 1558016196

Payments from drug & device makers

$8,536in general payments, 2019–2025

Across 165 payments — averaging $51.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Inspire Medical Systems, Inc.$2K
  • Livanova USA, Inc.$1K
  • AbbVie$897
  • Teva Pharmaceuticals USA, Inc.$251
  • Acadia Pharmaceuticals Inc$246
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$4,36351%
  • Food & beverage$4,16549%
  • Education$80%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,536 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$50,937
Medicare patients
269
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate21$143,312
RexultiBrexpiprazole68$131,624
Rufinamide12$34,926
BotoxOnabotulinumtoxina16$33,665
Memantine Hcl245$7,944
Levetiracetam140$7,164
Donepezil Hcl405$6,330
Carbidopa-LevodopaCarbidopa/Levodopa205$6,257
Emgality PenGalcanezumab-Gnlm12$5,605
Primidone160$4,189
Carbamazepine ErCarbamazepine28$3,865
Carbamazepine56$3,668
Memantine Hcl ErMemantine Hcl35$3,572
Rasagiline Mesylate14$2,011
Carbidopa-Levodopa ErCarbidopa/Levodopa34$1,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$246$143,31221 claims
Otsuka America Pharmaceutical, Inc.Rexulti$23$131,62468 claims
AbbVieBotox$897$33,66516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Deland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →